Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Net Income towards Common Stockholders: 2021-2025

Historic Net Income towards Common Stockholders for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to -$12.1 million.

  • SAB Biotherapeutics' Net Income towards Common Stockholders fell 16.60% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.8 million, marking a year-over-year increase of 14.91%. This contributed to the annual value of -$34.1 million for FY2024, which is 19.17% up from last year.
  • SAB Biotherapeutics' Net Income towards Common Stockholders amounted to -$12.1 million in Q3 2025, which was down 19.31% from -$10.1 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Net Income towards Common Stockholders ranged from a high of $1.4 million in Q1 2021 and a low of -$22.9 million during Q4 2023.
  • Over the past 3 years, SAB Biotherapeutics' median Net Income towards Common Stockholders value was -$7.4 million (recorded in 2023), while the average stood at -$9.4 million.
  • As far as peak fluctuations go, SAB Biotherapeutics' Net Income towards Common Stockholders slumped by 845.93% in 2023, and later spiked by 50.15% in 2024.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Net Income towards Common Stockholders stood at -$11.6 million in 2021, then soared by 31.83% to -$7.9 million in 2022, then tumbled by 190.26% to -$22.9 million in 2023, then skyrocketed by 50.15% to -$11.4 million in 2024, then declined by 16.60% to -$12.1 million in 2025.
  • Its Net Income towards Common Stockholders was -$12.1 million in Q3 2025, compared to -$10.1 million in Q2 2025 and -$5.2 million in Q1 2025.